Loading...

RXRX RECURSION PHARMACEUTICALS INC Management Changes 8-K Filing

RCRS

RXRX

RECURSION PHARMACEUTICALS INC

(RXRX)

2025 8-K

TUPELO Trial Data

Stock Registration Filing

Leadership Changes

Roche Collaboration

Acquisition Update

Financial Statements

Asset Acquisitions

Management Changes

Equity Offerings

Financial Statements

Board Appointments

Earnings Results

Investor Presentation

Stock Resale Registration

CFO Employment Agreement

Acquisition Update

Acquisition Details

Acquisition Completed

Acquisition Agreement

Acquisition Agreement

Q3 Financial Results

Acquisition Agreement

Acquisition Update

Acquisition Announcement

Acquisition Agreement

Public Offering

Press Release and Investor ...

Change in Registrant's Cert...

Results of Operations and F...

Appointment of Dr. Najat Kh...

Results of Operations and F...

Departure of Directors or C...

Bylaws Amendment

Regulation FD Disclosure

Partnership Agreement and I...

Master Agreement with Tempu...

Financial Results

Regulation FD Disclosure

Acquisition of Cyclica Inc.

Acquisition of Cyclica Inc.

Appointment, Acquisition

Earnings Reports

Regulation FD Disclosure

Financial Results Announcement

Management Changes

Investor Presentation

External Links:

On November 4, 2025, Recursion Pharmaceuticals appointed Najat Khan as CEO effective January 1, 2026, succeeding Christopher Gibson, who becomes Chair of the Board. Additionally, Dr. Khan's salary is set at $680,000, with equity awards totaling $1 million, and a future equity package potentially worth $7.5 million depending on committee approval.

AI Assistant

RECURSION PHARMACEUTICALS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.